Our guest today is Anand Anandkumar, CEO and MD of Bugworks Research, a clinical phase drug discovery company that is attempting to develop a new class of antibiotics to tackle what’s called ‘antimicrobial resistance,’ arising out of infectious bugs evolving to become resistant to multiple drugs. In this episode, Anand talks about the many challenges of commercialising scientific breakthroughs from India. He also talks about the opportunity for this country to become a biotech powerhouse.
(00:36) Intro to The Daily Tech Conversation
(00:49) Our guest today — Anand Anandkumar, CEO and MD of Bugworks Research
(02:00) A snapshot of Anand’s career and how he got interested in drug discovery
(05:27) An update on Bugworks’s first novel molecule in clinical trials
(09:02) Some early findings from R&D and clinical trials
(11:50) Next steps towards commercialisation
(15:12) Applications for the molecule, and market opportunity
(21:08) Thoughts on ways of accelerating drug discovery
(27:10) On what India could do more, to boost biotech research ventures
(31:54) Funding snapshot at Bugworks
(35:46) What investors are saying because of the current economic slowdown worries
(39:40) How India could do in drug discovery what it’s done in fintechMore about Anand Anandkumar and Bugworks
https://bugworksresearch.com/our-team/Theme music courtesy Free Music & Sounds:
https://soundcloud.com/freemusicandsounds